- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
GRAIL President Joshua Ofman Sells $3 Million in Stock
Insider sale represents 14% decrease in Ofman's GRAIL holdings
Apr. 9, 2026 at 11:09pm
Got story updates? Submit your updates here. ›
An insider sale by GRAIL's president highlights concerns about the biotech firm's financial outlook and valuation.Menlo Park TodayGRAIL, Inc. (NASDAQ:GRAL) President Joshua Ofman sold 61,665 shares of the company's stock on April 8th for a total transaction value of $3,078,316.80. Following the sale, Ofman now directly owns 371,216 shares in GRAIL, valued at $18,531,102.72, representing a 14.25% decrease in his position.
Why it matters
Insider transactions, especially large sales by company executives, can provide valuable insights into a firm's financial health and management's outlook. This sale by GRAIL's president raises questions about the company's near-term prospects and may signal concerns about the stock's valuation.
The details
Ofman sold the 61,665 GRAIL shares at an average price of $49.92, reducing his direct ownership stake in the company by 14.25%. GRAIL, a biotech firm focused on early cancer detection, has seen its stock price decline from a 52-week high of $118.84 amid broader market volatility.
- The share sale was executed on Wednesday, April 8, 2026.
The players
Joshua Ofman
President of GRAIL, Inc., a biotechnology company developing early cancer detection tests.
GRAIL, Inc.
A biotech company focused on developing multi-cancer early detection tests using advanced genomic and machine learning technologies.
What’s next
Investors will likely be closely watching GRAIL's stock performance and any further insider transactions in the coming weeks to gauge management's confidence in the company's outlook.
The takeaway
Ofman's substantial stock sale, while not necessarily indicative of broader issues, does raise questions about GRAIL's near-term prospects that the company will need to address to maintain investor confidence.
